Cargando…

Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease

BACKGROUND: We previously reported algorithms based on clinical parameters and plasma cell characteristics to identify patients with smoldering multiple myeloma (SMM) with higher risk of progressing who could benefit from early treatment. In this work, we analyzed differences in the immune bone marr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isola, Ignacio, Brasó-Maristany, Fara, Moreno, David F., Mena, Mari-Pau, Oliver-Calders, Aina, Paré, Laia, Rodríguez-Lobato, Luis Gerardo, Martin-Antonio, Beatriz, Cibeira, María Teresa, Bladé, Joan, Rosiñol, Laura, Prat, Aleix, Lozano, Ester, Fernández de Larrea, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646031/ https://www.ncbi.nlm.nih.gov/pubmed/34880879 http://dx.doi.org/10.3389/fimmu.2021.792609

Ejemplares similares

A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes
por: Schettini, Francesco, et al.
Publicado: (2022)

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
por: Prat, Aleix, et al.
Publicado: (2021)

Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution
por: Jiménez-Segura, Raquel, et al.
Publicado: (2022)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy
por: Moreno, David F., et al.
Publicado: (2021)

Treatment of Patients with Monoclonal Gammopathy of Clinical Significance
por: Moreno, David F., et al.
Publicado: (2021)

Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single Institution
por: Rodríguez-Lobato, Luis Gerardo, et al.
Publicado: (2023)

Advances in immunotyping of colorectal cancer
por: Wu, Yinhang, et al.
Publicado: (2023)

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
por: Díaz, Tania, et al.
Publicado: (2017)

Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma
por: Oliver-Caldes, Aina, et al.
Publicado: (2022)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
por: Guarneri, Valentina, et al.
Publicado: (2022)

Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia
por: Moreno, David F., et al.
Publicado: (2022)

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
por: Schettini, Francesco, et al.
Publicado: (2022)

Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer
por: Schettini, F., et al.
Publicado: (2021)

Gene expression profiles of breast cancer metastasis according to organ site
por: Brasó‐Maristany, Fara, et al.
Publicado: (2021)

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
por: Fernandez-Martinez, Aranzazu, et al.
Publicado: (2023)

A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma
por: Navarro, Alfons, et al.
Publicado: (2015)

The renal range of the κ/λ sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease
por: Molina-Andújar, Alícia, et al.
Publicado: (2020)

Identification and Validation of Tumor Stromal Immunotype in Patients With Hepatocellular Carcinoma
por: Li, Wei, et al.
Publicado: (2019)

Smoldering Multiple Myeloma
por: Gao, Minjie, et al.
Publicado: (2015)

Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer
por: Brasó-Maristany, Fara, et al.
Publicado: (2021)

Frequency and spectrum of PIK3CA somatic mutations in breast cancer
por: Martínez-Sáez, Olga, et al.
Publicado: (2020)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Brasó-Maristany, Fara, et al.
Publicado: (2020)

Natural killer cell immunotypes related to COVID-19 disease severity
por: Maucourant, Christopher, et al.
Publicado: (2020)

Deep Learning Reveals Key Immunosuppression Genes and Distinct Immunotypes in Periodontitis
por: Ning, Wanchen, et al.
Publicado: (2021)

High-dimensional immunotyping of tumors grown in obese and non-obese mice
por: Wogsland, Cara E., et al.
Publicado: (2021)

Immune Gene Signatures and Immunotypes in Immune Microenvironment Are Associated With Glioma Prognose
por: Wang, Xiang-Xu, et al.
Publicado: (2022)

Smoldering mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2017)

Metabolic Control of Smoldering Neuroinflammation
por: Peruzzotti-Jametti, Luca, et al.
Publicado: (2021)

Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2013)

First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma
por: Oliver-Caldes, Aina, et al.
Publicado: (2021)

Smoldering ashes : Cuzco and the creation of Republican Peru, 1780-1840 /
por: Walker, Charles, 1959-
Publicado: (1999)

Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization
por: Gomez-Macias, Gabriela Sofia, et al.
Publicado: (2020)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
por: Prat, Aleix, et al.
Publicado: (2022)

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2023)

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
por: Prat, Aleix, et al.
Publicado: (2023)

Smoldering cutaneous course of lymphomatoid granulomatosis
por: Russell, Devin P., et al.
Publicado: (2022)

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
por: Mathew, Divij, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_34n3vup9sdjvhol9qa42cs4qof